Atherosclerosis in HIV-positive patients;Arteriosklerose bei HIV-positiven patienten

Zeitschrift fur Kardiologie

Volumn 91, Issue 11, 2002, Pages 879-888

  Neumann, Till ^a   Miller, M ^a   Esser, S ^a   Gerken, G ^a   Erbel, R ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

AIDS; Arteriosclerosis; HAART; HIV infection

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ARTERIOSCLEROSIS; ATHEROSCLEROSIS; AUTOPSY; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LONG TERM CARE; MORBIDITY; MORTALITY; PATIENT; POPULATION; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; HIV INFECTIONS; HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 0036459018     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-002-0855-6     Document Type: Review

References (75)

1. Barbaro G, Di Lorenzo G, Grisorio B, Barbarini G (1998) Cardiac involvement in the acquired immunodeficiency syndrome: A multicenter clinical-pathological study. AIDS Res 14:1071-1077
2. Baroldi G, Corallo S, Moroni M, Repossini A, Mutinelli MR, Lazzarin A, Antonacci CM, Cristina S, Negri C (1988) Focal lmphocytic myocarditis in acquired immunodeficiency syndrome (AIDS): A correlative morphologic and clinical study in 26 consecutive fatal cases. J Am Coll Cardiol 12:463-469
3. Behrens G, Dejam A, Schmidt H, Balks HJ, Bradant G, Korner T, Stoll M, Schmidt RE (1999) Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13:F63-70
4. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE (1998) Vascular complications associated with use of HIV protease inhibitors. Lancet 351:1958-1959
5. Bernard SA (1996) Cardiac manifestations. In: Libman H, Witzburg RA (eds) HIV Infection: A primary Care Manual. Little Brown, Boston 123-137
6. Bernasconi E, Uhr M, Magenta L, Ranno A, Telenti A (Swiss HIV Cohort Study) (2001) Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. AIDS 15:1081-1082
7. Boers GH, Smals AG, Trijbels FJ, Fowler B, Bakkeren JA, Schoonderwaldt HC, Kleijer WJ, Kloppenborg PW (1985) Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 313:709-715
8. Bozzette SA, Ake C, Carpenter A, Bommakanty U, Leung V, Tam H, Smith R, Schepps A, Louis T (2002) Cardio- and Cerebrovascular Outcomes with Changing Process of Anti-HIV Therapy in 36766 US Veterans. CROI, Abstract LB9
9. Bussolino F, Mitola S, Serini G, Barillari G, Ensoli B (2001) Interactions between endothelial cells and HIV-1. Int J Biochem Biol 33:371-390
10. Calabrese LH, Estes M, Yen-Lieberman B, Proffitt MR, Tubbs R, Fishleder AJ, Levin KH (1989) Systemic vasculitis in association with human immunodeficiency virus infection. Arthitis Rheum 32:569-576
11. Cammarosano C, Lewis W (1985) Cardiac lesions in acquired immunodeficiency syndrome (AIDS). J Am Coll Cardiol 5:703-706
12. Capron L, Kim YU, Laurian C, Bruneval P, Fiessinger JN (1992) Atheroembolism in HIV-positive individuals. Lancet 340:1039-1040
13. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-58
14. Chen Y, Brennessel D, Walters J, Johnson M, Rosner F, Raza M (1999) Human immunodeficiency virus-associated pericardial effusion: Report of 40 cases and review of literature. Am Heart J 137:516-521
15. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G (2000) The effects of HIV infection on endothelial function. Endothelium 7:223-242
16. Constans J, Marchand JM, Conri C, Peuchant E, Seigneur M, Rispal P, Lasseur C, Pellegrin JL, Leng B (1995) Asymptomatic atherosclerosis in HIV-positive patients: A case-control ultrasound study. Annals of Medicine 27:683-685
17. Constans J, Pellegrin JL, Peuchant E, Dumon MF, Simonoff M, Clerc M, Leng B, Conri C (1993) High plasma lipoprotein (a) in HIV-positive patients. Lancet 341:1099-1100
18. Constans J, Wendling G, Peuchant E, Camilleri G, Conri C (1996) Lipoprotein (a) in 505 hospitalised patients with various pathological states: Correlation with cardiovascular disease and therapies. Int Angio 15:1-5
19. Danesh J, Collins R, Peto R (1997) Chronic infections and coronary artery disease: Is there a link? Lancet 350:430-436
20. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, Riesen W, Nicod P, Darioli R, Telenti A, Mooser V (Swiss HIV Cohort Study) (2001) Premature atherosclerosis in HIV-infected individuals: Focus on protease inhibitor therapy. AIDS 15:329-334
21. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrader LK, Phair JP (1998) Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280:1497-1503
22. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Minoz A (2001) Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 15:347-355
23. Dressler FA, Roberts WC (1989) Modes of death and types of cardiac diseases in opiate addicts: Analysis of 168 necropsy cases. Am J Cardiol 64:909-920
24. Dube MP, Johnson DL, Currier JS, Leedom JM (1997) Protease inhibitor-associated hyperglycaemia. Lancet 350:713-714
25. Dube MP, Sprecher D, Henry WK, Aberg JA, Torriani FJ, Hodis HN, Schouten J, Levin J, Myers G, Zackin R, Nevin T, Currier JS (2000) Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the adult AIDS clinical trial group cardiovascular disease focus group. Clin Inf Dis 31:1216-1224
26. Duong M, Buisson M, Cottin Y, Pi-roth L, Lhuillier I, Grappin M, Chavanet P, Wolff JE, Portier H (2001) Coronary heart disease associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors: Report of four cases and review. Clin Cardiol 24:690-694
27. Expert Panel of Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (1993) Summary of the second report of the NCEP expert panel. JAMA 269:3015-3023
28. Fink L, Reicheck N, Sutton MG (1984) Cardiac abnormalities in acquired immune deficiency syndrome. Am J Cardiol 54:1161-1163
29. Fisher SD, Lipshultz SE (2001) Cardiovascular abnormalities in HIV-infected individuals. In: Braunwald E (ed) Heart Disease: A Text Book of Cardiovascular Medicine. WB Saunders, Philadelphia 2211-2221
30. Gadallah MF, el-Shahawy MA, Campese VM, Todd JR, King JW (1996) Disparate prognosis of thrombotic microangiopathy in HIV-infected patients with and without AIDS. Am J Nephrol 16:446-450
31. Gherardi R, Belec L, Mhiri C, Gray F, Lescs MC, Sobel A, Guillevin L, Wechsler J (1993) The spectrum of vasculitis in human immunodeficiency virus-infected patients. A clinicopathologic evaluation. Arthritis Rheum 36:1164-1174
32. Hastillo A, Willis HE, Hess ML (1991) The heart as a target organ of immune injury. Curr Probl Cardiol 16:377-442
33. Henry K, Melroe H, Huebesch J, Hermundson J, Levine C, Swensen L, Daley J (1998) Severe premature coronary artery disease with protease inhibitors. Lancet 351:1328
34. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J (1998) Atorvastatin und gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 352:1031-1032
35. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH (1990) Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 15:1667-1687
36. Kaplan NM, Palmer BF (2000) AIDS vasculopathy. Am J Med Sci 320:379-387
37. Kaul S, Fishbein MC, Siegel RJ (1991) Cardiac manifestation of acquired immunodeficiency syndrome. Am Heart J 122:535-544
38. Klein D, Hurley L (2002) Hospitalizations for Coronary Heart Disease and Myocardial Infarction Among HIV+ Patients in the HAART Era. CROI, Abstract 696T
39. Kovanen PT, Manttari M, Palosuo T, Manninen V, Aho K (1998) Predictions of myocardial infarction in dislipidemic men by elevated levels of immunoglobulin cases A, E, and F, but not M. Arch Intern Med 158:1434-1439
40. Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, Perilli F, Lillo A, Ferraro S, Gargiulo M, Chirianni A, Angarano G, Regina G, Pastore G (2000) Premature lesions of the carotid vessels in HIV-1 infected patients treated with protease inhibitors. AIDS 14:123-128
41. Majid PA, Patel B, Kim HS, Zimmerman JL, Dellinger RP (1990) An angiographic and histologic study of cocaine-induced chest pain. Am J Cardiol 65:812-814
42. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM (1995) A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 333:1534-1539
43. Mauss S, Wolf E, Jaeger H (1999) Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors. Ann Intern Med 130:162-163
44. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA (2000) HIV-related pulmonary hypertension. Chest 118:1133-1141
45. Melnick JL, Adam E, DeBakey ME (1990) Possible role of cytomegalovirus in atherosgenesis JAMA 263: 2204-2222
46. Morgello S, Mahboob R, Yakoushina T, Khan S, Hague K (2002) Autopsy findings in a human immunodeficiency virus-infected population over 2 decades. Arch Pathol Lab Med 126:182-190
47. Moyle GJ, Lloyd M, Reynolds B, Baldwin C, Mandalia S, Gazzard BG (2001) Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 15:1503-1508
48. Neunteufl T, Heher S, Katzenschlager R, Wolfl G, Kostner K, Maurer G, Weidinger F (2000) Late prognostic value of flow-mediated vasodilatation in the brachial artery of patients with chest pain. Am J Cardiol 86:207-210
49. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C (2001) Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 15:F11-F18
50. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860
51. Passalaris JD, Sepkowitz KA, Glesby MJ (2000) Coronary artery disease and human immunodeficiency virus infection. Clin Inf Dis 31:787-797
52. Paton P, Tabib A, Loire R, Tete R (1993) Coronary artery lesions and human immunodeficiency virus infection. Res Virol 144:225-231
53. Penzak SR, Chuck SK (2000) Hyperlipidemia associated with HIV protease inhibitor use: Pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 32:111-123
54. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V (Swiss Cohort Study) (1999) Atherogenic dyslipidaemia in HIV-infected individuals treated with proteinase inhibitors. Circulation 100:700-705
55. Petrosillo N, Pellicelli AM, Boumis E, Ippolito G (2001) Clinical manifestation of HIV-related pulmonary hypertension. Ann N Y Acad Sci 946:223-235
56. Robert-Koch-Institut (2001) Epidemiologisches Bulletin: Sonderausgabe A; HIV/AIDS-Bericht 11/2001
57. Sattler FR, Qian D, Louie S, Johnson D, Briggs W, DeQuattro V, Dube MP (2001) Elevated blood pressure in subjects with lipodystrophy. AIDS 15:2001-2010
58. Schachinger V, Briton MB, Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101:1899-1906
59. Schecter AD, Berman AB, Yi L, Mosoian A, McManus CM, Berman JW, Klotman ME, Taubman MB (2001) HIV envelope gp120 activates human arterial smooth muscle cells. PNAS 98:10142-10147
60. Speich R et al (1991) Primary pulmonary hypertension in HIV infection. Chest 100:1268-1271
61. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, Sosman JM (2001) Use of human immunodeficiency virus-1 protease inhibitors is associated with aterogenic lipoprotein changes and endothelial dysfunction. Circulation 104:257-262
62. Stocker DN, Meier PJ, Stoller R, Fattinger KE (1998) «Buffalo hump» in HIV-1 infection. Lancet 352:320-321
63. Sullivan AK, Nelson MR (1997) Marked hyperlipidaemia on ritonavir therapy. AIDS 11:938-939
64. Sutor GC, Schmidt RE, Albrecht H (1999) Thrombotic microangiopathies and HIV infection: Report of two typical cases features of HUS and TTP, and review of the literature. Infection 27:12-15
65. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A (2000) Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101:948-954
66. Tabib A, Greenland T, Mercier I, Loire R, Mornex JF (1992) Coronary lesions in young HIV-positive subjects at necropsy. Lancet 340:730
67. Tabib A, Leroux C, Mornex JF, Loire R (2000) Accelerated coronary arteriosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coronary Artery Disease 11:41-46
68. Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, Satomura K, Ohsuzu F, Kurita A (1998) Endothelium-dependent flow-mediated vasodilatation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 82:1535-1539
69. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME (1994) Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 91:6369-6373
70. Ullrich CK, Groopman JE, Ganju RK (2000) HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood 96:1438-1442
71. UNAIDS (2001) AIDS-epidemic Update - December 2001
72. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, Glesby M, Behrens G, Clotet B, Stellato RK, Molhuizen HO, Reiss P (The Atlantic Study Team) (2001) Nivirapine-containig antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 15:2407-2414
73. Visnegarwala F, Krause KI, Musher DM (1997) Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 127:349
74. Vittecoq D, Escaut L, Monsuez J (1998) Vascular complications associated with the use of HIV protease inhibitors. Lancet 351:1959
75. Walli R, Goebel FD, Demant T (1997) Impaired glucose tolerance of protease inhibitors. Ann Intern Med 127:947